Ruediger Liersch

Summary

Country: Germany

Publications

  1. doi request reprint Lymphangiogenesis in cancer: current perspectives
    Ruediger Liersch
    Department of Medicine, Hematology Oncology, University Hospital Munster, Albert Schweitzer Str 33, 48129, Munster, Germany
    Recent Results Cancer Res 180:115-35. 2010
  2. pmc Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor
    Ruediger Liersch
    Department of Medicine, Hematology and Oncology, University Hospital Muenster, D 48129 Muenster, Germany
    Int J Oncol 41:1455-63. 2012
  3. pmc Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator
    Ruediger Liersch
    Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Int J Oncol 41:2073-8. 2012
  4. doi request reprint Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients
    Ruediger Liersch
    Department of Medicine A Hematology and Oncology, University Hospital of Muenster, Muenster, Germany
    Blood 119:5215-20. 2012
  5. ncbi request reprint Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile
    Johannes Dreischalück
    Department of Medicine A, University of Muenster, D 48129 Muenster, Germany
    Int J Oncol 37:1389-97. 2010
  6. doi request reprint S100A2 induces metastasis in non-small cell lung cancer
    Etmar Bulk
    Department of Medicine, Hematology and Oncology, University of Munster, Munster, Germany
    Clin Cancer Res 15:22-9. 2009
  7. ncbi request reprint Generation of fusion proteins for selective occlusion of tumor vessels
    Torsten Kessler
    Department of Medicine Hematology and Oncology, University of Muenster, Albert Schweitzer Strasse 33, D 48129 Muenster, Germany
    Curr Drug Discov Technol 5:1-8. 2008
  8. doi request reprint Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy
    Iris Appelmann
    Department of Medicine Hematology and Oncology, University of Munster, Albert Schweitzer Strasse 33, 48129, Munster, Germany
    Recent Results Cancer Res 180:51-81. 2010
  9. doi request reprint Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor
    Christian Schwöppe
    Department of Medicine A, Hematology, Oncology and Pneumology, University of Muenster, Albert Schweitzer Campus 1, D 48129 Muenster, Germany
    J Med Chem 56:2337-47. 2013
  10. doi request reprint Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer
    Niels Reinmuth
    Department of Medicine Hematology and Oncology and the IZKF Muenster, University of Muenster, Muenster, Germany
    Int J Cancer 124:1535-44. 2009

Collaborators

Detail Information

Publications17

  1. doi request reprint Lymphangiogenesis in cancer: current perspectives
    Ruediger Liersch
    Department of Medicine, Hematology Oncology, University Hospital Munster, Albert Schweitzer Str 33, 48129, Munster, Germany
    Recent Results Cancer Res 180:115-35. 2010
    ..Advances in our understanding of the mechanisms have translated into a number of novel therapeutic studies...
  2. pmc Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor
    Ruediger Liersch
    Department of Medicine, Hematology and Oncology, University Hospital Muenster, D 48129 Muenster, Germany
    Int J Oncol 41:1455-63. 2012
    ..Treatment of cultured lymphatic endothelial cells (LECs) with osteopontin promoted cell migration mediated by the integrin α9 pathway. Our results identify osteopontin as a novel lymphangiogenic factor...
  3. pmc Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator
    Ruediger Liersch
    Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Int J Oncol 41:2073-8. 2012
    ..In cases of tumor-free lymph nodes the increased lymphatic network of sentinel lymph nodes is a very early premetastatic sign and may provide a new prognostic indicator and target for aggressive diseases...
  4. doi request reprint Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients
    Ruediger Liersch
    Department of Medicine A Hematology and Oncology, University Hospital of Muenster, Muenster, Germany
    Blood 119:5215-20. 2012
    ..0002) and OS (P = .001). The prognostic role of OPN was most prominent in intermediate-risk AML. These data provide evidence that OPN expression is an independent prognostic factor in AML...
  5. ncbi request reprint Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile
    Johannes Dreischalück
    Department of Medicine A, University of Muenster, D 48129 Muenster, Germany
    Int J Oncol 37:1389-97. 2010
    ..Thus, subcutaneous injection of tTF-NGR represents an active, but toxic application procedure and compares unfavourably to intravenous infusion...
  6. doi request reprint S100A2 induces metastasis in non-small cell lung cancer
    Etmar Bulk
    Department of Medicine, Hematology and Oncology, University of Munster, Munster, Germany
    Clin Cancer Res 15:22-9. 2009
    ..In this study, we analyzed the prognostic role of mRNA levels of all S100 proteins in early stage non-small cell lung cancer (NSCLC) patients as well as the pathogenetic of S100A2 in the development of metastasis in NSCLC...
  7. ncbi request reprint Generation of fusion proteins for selective occlusion of tumor vessels
    Torsten Kessler
    Department of Medicine Hematology and Oncology, University of Muenster, Albert Schweitzer Strasse 33, D 48129 Muenster, Germany
    Curr Drug Discov Technol 5:1-8. 2008
    ..Thus, generation and screening of active fusion proteins, which induce selective thrombosis in the tumor vasculature, may be a promising strategy for the development of new drugs as cancer therapeutics...
  8. doi request reprint Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy
    Iris Appelmann
    Department of Medicine Hematology and Oncology, University of Munster, Albert Schweitzer Strasse 33, 48129, Munster, Germany
    Recent Results Cancer Res 180:51-81. 2010
    ..Thus, it is important to understand the physiology of VEGF and PDGF and their receptors as well as their roles in malignancies in order to develop antiangiogenic strategies for the treatment of malignant disease...
  9. doi request reprint Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor
    Christian Schwöppe
    Department of Medicine A, Hematology, Oncology and Pneumology, University of Muenster, Albert Schweitzer Campus 1, D 48129 Muenster, Germany
    J Med Chem 56:2337-47. 2013
    ..Results demonstrate that PEGylation can significantly improve the therapeutic range of tTF-NGR...
  10. doi request reprint Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer
    Niels Reinmuth
    Department of Medicine Hematology and Oncology and the IZKF Muenster, University of Muenster, Muenster, Germany
    Int J Cancer 124:1535-44. 2009
    ..These studies demonstrate that combined inhibition of PDGFRalpha and -beta results in markedly decreased tumor growth in vivo because of impaired recruitment of periendothelial cells...
  11. doi request reprint Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma
    Michele Pohlen
    Department of Medicine A, Hematology Oncology, University Hospital Muenster, Muenster, Germany
    Am J Hematol 86:E61-4. 2011
    ..Furthermore, we additionally amended supportive care with palifermin as it reduced severity and prevalence of mucositis [5]...
  12. doi request reprint Tissue-factor fusion proteins induce occlusion of tumor vessels
    Christian Schwöppe
    Department of Medicine Hematology and Oncology, University of Muenster, Albert Schweitzer Strasse 33, Muenster, Germany
    Thromb Res 125:S143-50. 2010
    ....
  13. ncbi request reprint Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia
    Ruediger Liersch
    Department of Medicine Hematology and Oncology, University of Muenster, Albert Schweitzer Strasse 33, D 48129 Muenster, Germany
    Leuk Res 32:954-61. 2008
    ..Although expression levels display no prognostic significance in our study, strategies targeting the VEGF-C/VEGFR-3-pathway might be a promising treatment approach...
  14. doi request reprint POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience
    Gabriela B Thoennissen
    Department of Medicine, Hematology Oncology, University of Muenster, Muenster, Germany
    Ann Hematol 91:1419-25. 2012
    ..In line with previous single-center reports, melphalan HDT followed by ABSCT proved to be a first-line treatment option with tolerable side effects in severely affected POEMS patients with progressing symptoms...
  15. doi request reprint Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use
    Ruediger Liersch
    Department of Haematology and Oncology, Internal Medicine III, Clemenshospital Muenster, Muenster, Germany
    Br J Haematol 165:17-38. 2014
    ..Despite the high number of established risk factors, only few predictive markers exist which can truly aid therapy decisions in patients with AML...
  16. ncbi request reprint Lymphangiogenesis in development and disease
    Ruediger Liersch
    Department of Medicine, Hematology and Oncology, University Hospital Muenster, Muenster, Germany
    Thromb Haemost 98:304-10. 2007
    ..Based upon these findings, novel therapeutic strategies are currently being developed that aim at inhibiting or promoting the formation and function of lymphatic vessels in disease...
  17. doi request reprint Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice
    Etmar Bulk
    Departments of Medicine, Hematology and Oncology, University of Munster, Munster, Germany
    Cancer Res 68:1896-904. 2008
    ..05). These findings suggest that RNA interference-based therapy approaches can be highly effective in the adjuvant setting...